Lilly Drug Receives Approval in Japan

Posted: Updated:
INDIANAPOLIS -

The Japan Ministry of Health, Labor and Welfare has granted Indianapolis-based Eli Lilly and Co. (NYSE: LLY) and Delaware-based Incyte Corp. (Nasdaq: INCY) marketing approval for a once-daily treatment of rheumatoid arthritis. Lilly says the approval for Olumiant is based on four phase 3 clinical trials.

The approval is for 2-mg and 4-mg tablets of Olumiant, also known as baricitinib, which Lilly says will be used by patients with inadequate responses to standard-of-care therapies. The pharmaceutical company says the clinical trials included more than 3,000 moderate-to-severe RA patients throughout the world, including more than 500 from Japan.

"Today is an important milestone for the RA community in Japan," said Christi Shaw, president of Lilly Bio-Medicines. "Olumiant has been shown to provide effective relief of RA symptoms in people who do not respond to standard treatments, as well as prevent the structural damage to joints that makes RA a progressive, debilitating disease."

Lilly says the approval triggers a $15 million milestone payment from Lilly to Incyte, which is expected to occur in the third quarter.

Earlier this year, the U.S. Food and Drug Administration rejected a new drug application for the treatment, saying more clinical results were needed. 

  • Perspectives

    • The Power of Partnerships

      You can't go it alone in tech. All technology companies, regardless of their segment, live in an ecosystem comprised of organisms of varying complexity. More mature companies in established categories can function at the top of the food chain, consuming smaller companies through acquisition, but startups are seldom if ever in a position to gain dominance through acquisition. It’s vital for the success of a startup to be able to play well with others...

    More

Subscribe

Name:
Company Name:
Email:
Confirm Email:
HTML
INside Edge
Morning Briefing
BigWigs & New Gigs
Life Sciences Indiana
Indiana Connections
INPower
Subscribe
Unsubscribe

Events



  • Most Popular Stories

    • Liberty Mutual Plans 400 New Carmel Jobs

      Boston-based Liberty Mutual Group Inc. is planning to add up to 400 Carmel jobs as part of a $14 million expansion plan. The insurance company has a global presence and currently employs 1,430 in central Indiana. The Indiana Economic Development Corp. says the new jobs, expected to be created by 2021, will pay more than the state and Hamilton County average wages. Plans call for Liberty Mutual to lease...

    • Alliance Française Moves HQ to Carmel

      The Indianapolis chapter of the Alliance Française has relocated its headquarters to Carmel. The organization says the new located, at Pedcor Square in Carmel City Center, is a strategic location due to a large number of its members residing in the Hamilton County city. 

    • Opioid Withdrawal Treatment Lands FDA Clearance

      The U.S. Food and Drug Administration has given clearance for a medical device developed in Indiana to help treat symptoms of opioid withdrawal. The device, known as the NSS-2 BRIDGE, was created by Innovative Health Solutions Inc. in Versailles.

    • LCI Industries Adds RV Vet to Board

      A well-known figure on the northern Indiana recreational vehicle scene is joining the Elkhart-based LCI Industries (NYSE: LCII) board. Grand Design Recreational Vehicle Co. co-founder Ron Fenech, who previously held executive positions with Thor Industries Inc. (NYSE: THO) and Keystone RV Co., will also serve on the LCI board's corporate governance and nominating committee.

    • Coal Loading Facility Planned For Princeton

      A subsidiary of Denver-based Hallador Energy Co. (Nasdaq: HNRG) has announced plans to construct a new truck-to-rail coal loading facility near Princeton. Sunrise Coal LLC in Terre Haute says the facility, known as the Princeton Loop, is expected to be complete in the spring of 2018.